Results 41 to 50 of about 28,326 (256)

Plasma ctDNA TP53 Mutation and Breast Cancer Prognosis: A Systematic Review and Meta-Analysis

Xiehe Yixue Zazhi
ObjectiveTo analyze the association between plasma circulating tumor DNA (ctDNA) TP53 mutation status and survival outcomes in breast cancer patients.MethodsPubMed, Embase, and the Cochrane Library were searched for relevant literature published between ...
FAN Hao, LIANG Annan, ZOU Wei, GAO Guangxi, LIU Lijin, LIU Fei, ZHAO Lina, WU Zhihong   +7 more
doaj   +1 more source

Regulatory implications of ctDNA in immuno-oncology for solid tumors

, 2023
In the era of precision oncology, use of circulating tumor DNA (ctDNA) is emerging as a minimally invasive approach for the diagnosis and management of patients with cancer and as an enrichment tool in clinical trials.
Richard Pazdur, Shenghui Tang, Erik W Bloomquist, Julia A Beaver, Paz J Vellanki, Reena Philip, Harpreet Singh, Anand Pathak, Michael J Fusco, Soma Ghosh   +9 more
core   +1 more source

Pan-cancer screening by circulating tumor DNA (ctDNA) – recent breakthroughs and chronic pitfalls

Journal of Laboratory Medicine, 2022
Early detection is crucial for optimal treatment and prognosis of cancer. New approaches for pan-cancer screening comprise the comprehensive characterization of circulating tumor DNA (ctDNA) in plasma by next generation sequencing and molecular profiling
Holdenrieder Stefan, Ungerer Vida, Oberhofer Angela, Bronkhorst Abel Jacobus   +3 more
doaj   +1 more source

Measurement of ctDNA at first evaluation.

, 2016
Evolution of ctDNA concentration (ng/mL) between baseline (T0) and first evaluation (E1) showing a (A) decrease, (B) increase, (C) normalization, or (D) negativity at both time points. (E) PFS according to ctDNA evolution between T0 and E1. (F) Waterfall
Eleonora Zonta (3153192), Audrey Didelot (3153195), Constance Thibault (3603650), Yves Rozenholc (3603653), Elizabeth Fabre (187892), Camille Lours (3603656), Nicolas Pécuchet (3153186), Pierre Combe (3603659), Pierre Laurent-Puig (56604), Laure Gibault (228316), Hélène Blons (187905), Valérie Taly (3153189)   +11 more
core   +1 more source

Quantitative ctDNA Detection in Hepatoblastoma: Implications for Precision Medicine

, 2023
Hepatoblastoma is characterized by driver mutations in CTNNB1, making it an attractive biomarker for a liquid biopsy approach utilizing circulating tumor DNA (ctDNA).
James Torpy, Sarah E. Woodfield, Andre E. Minoche, Anna Mullins, Sanjeev A. Vasudevan, Lucy E. Cain, Geoffrey McCowage, Smadar Kahana-Edwin, Jonathan Karpelowsky, Dan P. T. Shea, Sarah Kummerfeld, Andres F. Espinoza, Leonard D. Goldstein   +12 more
core   +1 more source

Lung cancer ctDNA sequencing.

, 2016
Lung cancer ctDNA sequencing.
Melissa M. Pentony (3119964), Avinash Gupta (3119970), Pamela J. Kaisaki (52706), Carme Camps (278092), Anthony Cutts (3119985), Jenny C. Taylor (113518), Denis C. Talbot (3119982), Kulvinder Kaur (18480), Shirley Henderson (3119961), Ioannis Karydis (379289), Anna Schuh (3119973), Suzanne Page (3119976), Mark R. Middleton (3119988), Niko Popitsch (795982), Gareth Wilson (3119967), Dimitris Vavoulis (3119979)   +15 more
core   +1 more source

ESR1 methylation and ESR1 mutations in circulating tumor cells (CTCs) and paired plasma‐cfDNA of advanced breast cancer patients: A feasibility proof‐of‐concept study

Molecular Oncology, EarlyView.
Circulating tumor cells (CTCs) and plasma cell‐free DNA (cfDNA) were analyzed to detect ESR1 mutations and methylation in patients with advanced breast cancer. CTC‐derived DNA showed higher sensitivity for mutation detection and revealed complementary genetic and epigenetic alterations, highlighting the added value of CTC analysis for understanding ...
Dimitra Stergiopoulou, Athina Markou, Eleonora Nicolo, Mara S Serafini, Qiang Zhang, Youbin Zhang, Lorenzo Gerratana, Andrew A. Davis, Huiping Liu, William J Gradishar, Carolina Reduzzi, Massimo Cristofanilli, Evi Lianidou   +12 more
wiley   +1 more source

Potential value of ctDNA monitoring in metastatic HR + /HER2 − breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial

, 2023
Background There is increasing interest in the use of liquid biopsies, but data on longitudinal analyses of circulating tumor DNA (ctDNA) remain relatively limited.
Joanne Chiu, Mukta Joshi, O. Alejandro Balbin, Tomoyuki Aruga, Yoon-Sim Yap, Naveen Babbar, Fei Su, Takashi Ishikawa, Juan Pablo Zarate, Norikazu Masuda   +9 more
core   +1 more source

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

Molecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, Iris te Paske, Vanja de Weerd, Corine M. Beaufort, Hans M. Westgeest, Jens Voortman, Maureen J. B. Aarts, Maud Rijnders, Astrid A. M. van der Veldt, Ronald de Wit, Niven Mehra, Saskia M. Wilting, Debbie G. J. Robbrecht   +14 more
wiley   +1 more source

ctDNA at tumor progression.

, 2016
(A) Time to RECIST progression and time to ctDNA progression in 47 patients with positive ctDNA at time of progression (ToP). (B) Mutations detected in plasma at baseline (T0) and at time of progression (ToP) (n = 66 patients).
Eleonora Zonta (3153192), Audrey Didelot (3153195), Constance Thibault (3603650), Yves Rozenholc (3603653), Elizabeth Fabre (187892), Camille Lours (3603656), Nicolas Pécuchet (3153186), Pierre Combe (3603659), Pierre Laurent-Puig (56604), Laure Gibault (228316), Hélène Blons (187905), Valérie Taly (3153189)   +11 more
core   +1 more source